114 related articles for article (PubMed ID: 9665012)
1. Malononitrilamides synergistically prevent acute and treat ongoing skin allograft rejection with cyclosporine.
Schorlemmer HU; Ruuth E; Kurrle R
Transpl Int; 1998; 11 Suppl 1():S340-4. PubMed ID: 9665012
[TBL] [Abstract][Full Text] [Related]
2. Synergistic activity of malononitrilamides with cyclosporine to control and reverse xenograft rejection.
Schorlemmer HU; Kurrle R
Int J Tissue React; 1997; 19(3-4):149-56. PubMed ID: 9506316
[TBL] [Abstract][Full Text] [Related]
3. Synergism of the malononitrilamides 279 and 715 with cyclosporine A in the induction of long-term cardiac allograft survival.
Lindner JK; Zantl N
Transpl Int; 1998; 11 Suppl 1():S303-9. PubMed ID: 9665002
[TBL] [Abstract][Full Text] [Related]
4. Malononitrilamides 715 and 279 prevent accelerated cardiac allograft rejection synergistically with cyclosporin A in presensitized rats.
Qi Z; Simanaitis M; Ekberg H
Transpl Immunol; 1998 Jun; 6(2):94-100. PubMed ID: 9777697
[TBL] [Abstract][Full Text] [Related]
5. Acute skin graft rejection can be prevented and treated in rat models by malononitrilamides.
Schorlemmer HU; Schwab W; Ruuth E; Kurrle R
Transplant Proc; 1996 Dec; 28(6):3048-50. PubMed ID: 8962182
[No Abstract] [Full Text] [Related]
6. Regulation of alloreactivity in the popliteal lymph node assay by the new immunosuppressants: malononitrilamides.
Schorlemmer HU; Ruuth E; Kurrle R
Transpl Int; 1998; 11 Suppl 1():S448-51. PubMed ID: 9665036
[TBL] [Abstract][Full Text] [Related]
7. The alloreactivity in the popliteal lymph node (PLN) assay is regulated by malononitrilamides (MNAs).
Schorlemmer HU; Ruuth E; Kurrle R
Int J Tissue React; 1997; 19(3-4):157-61. PubMed ID: 9506317
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat.
Bilolo KK; Ouyang J; Wang X; Zhu S; Jiang W; Qi S; Xu D; Hebert MJ; Bekersky I; Fitzsimmons WE; Chen H
Transplantation; 2003 Jun; 75(11):1881-7. PubMed ID: 12811249
[TBL] [Abstract][Full Text] [Related]
9. Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin.
Qi Z; Ekberg H
Scand J Immunol; 1998 Oct; 48(4):379-88. PubMed ID: 9790308
[TBL] [Abstract][Full Text] [Related]
10. Malononitrilamides reduce IgM and IgG xenoantibodies and prolong skin xenograft survival in a mouse-to rat model.
Schorlemmer HU; Kurrle R
Transplant Proc; 1998 Jun; 30(4):976-9. PubMed ID: 9636394
[No Abstract] [Full Text] [Related]
11. Control of mouse-to-rat skin xenograft rejection by malononitrilamides.
Schorlemmer HU; Kurrle R
Transplant Proc; 1996 Dec; 28(6):3037-9. PubMed ID: 8962179
[No Abstract] [Full Text] [Related]
12. Long-term allograft survival and tolerance induction by the synergistic activity of malononitrilamides and tacrolimus.
Schorlemmer HU; Bartlett RR; Lindner JK; Kurrle R
Transplant Proc; 1998 Dec; 30(8):4099-103. PubMed ID: 9865312
[No Abstract] [Full Text] [Related]
13. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model.
Schorlemmer HU; Bartlett RR; Lindner JK; Kurrle R
Transplant Proc; 1999; 31(1-2):1184-8. PubMed ID: 10083529
[No Abstract] [Full Text] [Related]
14. Long-term xenograft survival by combination therapy of malononitrilamide MNA 715 with cyclosporine.
Schorlemmer HU; Kurrle R
Transplant Proc; 1997 Dec; 29(8):3501-4. PubMed ID: 9414811
[No Abstract] [Full Text] [Related]
15. Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejection.
Aharoni R; Yussim A; Sela M; Arnon R
Int Immunopharmacol; 2005 Jan; 5(1):23-32. PubMed ID: 15589456
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus versus cyclosporin A: a comparative study on rat renal allograft survival.
Jiang H; Sakuma S; Fujii Y; Akiyama Y; Ogawa T; Tamura K; Kobayashi M; Fujitsu T
Transpl Int; 1999; 12(2):92-9. PubMed ID: 10363590
[TBL] [Abstract][Full Text] [Related]
17. The new immunosuppressants, the malononitrilamides MNA 279 and MNA 715, inhibit various graft-vs.-host diseases (GvHD) in rodents.
Schorlemmer HU; Kurrle R; Bartlett RR
Drugs Exp Clin Res; 1997; 23(5-6):167-73. PubMed ID: 9515226
[TBL] [Abstract][Full Text] [Related]
18. FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation.
Yamamoto S; Okuda T; Yamasaki K; Tanaka H; Kubo S; Takemura S; Ikeda K; Minamiyama Y; Hirohashi K; Suehiro S
Transplantation; 2004 Dec; 78(11):1618-25. PubMed ID: 15591950
[TBL] [Abstract][Full Text] [Related]
19. The prevention of accelerated cardiac allograft rejection in sensitized recipients after treatment with brequinar sodium.
Yasunaga C; Cramer DV; Chapman FA; Wang HK; Barnett M; Wu GD; Makowka L
Transplantation; 1993 Oct; 56(4):898-904. PubMed ID: 8212214
[TBL] [Abstract][Full Text] [Related]
20. Leflunomide analog, MNA-715, plus cyclosporine reduces renal allograft rejection in mismatched dogs.
Kyles AE; Gregory CR; Griffey SM; Bernsteen L; Jackson J; Morris RE
Transplant Proc; 2001; 33(1-2):368-9. PubMed ID: 11266865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
